Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer

• DOI: 10.3109/0284186x.2012.754990
• Publication Date: 2013-01-18T06:44:24Z
• Authors: Gaetano Aurilio; Lorenzo Monfardini; Stefania Rizzo; Angela Sciandivasci; Lorenzo Preda; Vincenzo Bagnardi; Davide Disalvatore; Giancarlo Pruneri; Elisabetta Munzone; Paolo Della Vigna; Giuseppe Renne; Massimo Bellomi; Giuseppe Curigliano; Aron Goldhirsch; Franco Nolè
• Keywords: Progesterone receptor; Concordance; McNemar's test; Primary tumor

Background. In patients with metastatic breast cancer, the evaluation of biological characteristics bone deposits may be a valuable adjunct in clinical practice. We assessed discordance expression levels for estrogen receptor (ER), progesterone (PgR) and human epidermal growth factor 2 (HER2) between primary tumor metastases its impact on patient management. Material methods. retrospectively reviewed 363 CT-guided biopsies performed from January 1997 to December 2009. The proportions ER, PgR HER2 positive tumors at diagnosis metastases, determined by IHC and/or FISH, were compared using McNemar's test. biopsy reassessment treatment choice was evaluated Fisher's exact Results. selected 109 cancer histologically confirmed metastases. Among 107 assessable overall rate detected 22 (20.5%) 47 (43.9%) ER PgR, respectively, six 86 (6.9%) status. indication change endocrine therapy occurred 62% 30% concordance, respectively (p = 0.01). targeted 67% 8% 0.002). Conclusions. confirm that including biology should considered, since it is likely choice.